Drug Development Pipeline
This compound is an inhaled dry powder formulation of a cationic airway liquid modulator. It has anti-inflammatory properties and increases mucociliary clearance.
No further clinical development is planned at this time.
The program was sponsored by Pulmatrix and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More